drugset / Trial / NCT00002172
An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml
Completed
The Immune Response Corporation
Open-labelTreatment
Summary
To provide product through an expanded access program to HIV-infected patients with CD4 counts less than 300 cells/ml.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remune | Vaccine | — | — |